The Effects of ARID1A Mutation in Gastric Cancer and Its Significance for Treatment

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2023 Nov 26

PMID 38008753

Authors

Shan Lu

Ruifeng Duan

Liang Cong

Ying Song

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) has emerged as a significant issue in public health all worldwide as a result of its high mortality rate and dismal prognosis. AT-rich interactive domain 1 A (ARID1A) is a vital component of the switch/sucrose-non-fermentable (SWI/SNF) chromatin remodeling complex, and ARID1A mutations occur in various tumors, leading to protein loss and decreased expression; it then affects the tumor biological behavior or prognosis. More significantly, ARID1A mutations will likely be biological markers for immune checkpoint blockade (ICB) treatment and selective targeted therapy. To provide theoretical support for future research on the stratification of individuals with gastric cancer with ARID1A as a biomarker to achieve precision therapy, we have focused on the clinical significance, predictive value, underlying mechanisms, and possible treatment strategies for ARID1A mutations in gastric cancer in this review.

Citing Articles

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Jaidee R, Jusakul A, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A Sci Rep. 2025; 15(1):8621.

PMID: 40074934 PMC: 11904213. DOI: 10.1038/s41598-025-93192-1.

Genomic landscape and potential therapeutic targets in alpha-fetoprotein-producing gastric cancer.

Zan L, Zhang X, Shen L, Zhao Q, Tan D, Peng X Gastric Cancer. 2025; .

PMID: 39928247 DOI: 10.1007/s10120-025-01594-x.

Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology.

Tan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B Curr Issues Mol Biol. 2024; 46(7):6533-6565.

PMID: 39057032 PMC: 11276574. DOI: 10.3390/cimb46070390.

Genomic events stratifying prognosis of early gastric cancer.

Molinari C, Solaini L, Rebuzzi F, Tedaldi G, Angeli D, Petracci E Gastric Cancer. 2024; 27(6):1189-1200.

PMID: 39028418 PMC: 11513700. DOI: 10.1007/s10120-024-01536-z.

Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation.

Angelico G, Attanasio G, Colarossi L, Colarossi C, Montalbano M, Aiello E Cancers (Basel). 2024; 16(11).

PMID: 38893181 PMC: 11171396. DOI: 10.3390/cancers16112062.

References

Dong Z, Wu S, Liao R, Huang S, Wu Y . Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. Tumour Biol. 2016; 37(4):4251-61. DOI: 10.1007/s13277-016-4812-9. View

Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski C, Galle P . Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol. 2012; 69(6):1601-15. DOI: 10.1007/s00280-012-1869-z. View

Giraud J, Bouriez D, Seeneevassen L, Rousseau B, Sifre E, Giese A . Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination. Cancers (Basel). 2019; 11(4). PMC: 6520896. DOI: 10.3390/cancers11040560. View

Wang F, Wei X, Wang F, Xu N, Shen L, Dai G . Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019; 30(9):1479-1486. PMC: 6771223. DOI: 10.1093/annonc/mdz197. View

Luo B, Cheung H, Subramanian A, Sharifnia T, Okamoto M, Yang X . Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008; 105(51):20380-5. PMC: 2629277. DOI: 10.1073/pnas.0810485105. View

Zhang Q, Yan H, Wang J, Cui S, Wang X, Jiang Y . Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget. 2016; 7(29):46127-46141. PMC: 5216786. DOI: 10.18632/oncotarget.10060. View

Ibarrola-Villava M, Llorca-Cardenosa M, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo J . Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. Oncotarget. 2015; 6(29):26935-45. PMC: 4694964. DOI: 10.18632/oncotarget.4775. View

Kim Y, Ham I, Hur H, Lee D . Various ARID1A expression patterns and their clinical significance in gastric cancers. Hum Pathol. 2016; 49:61-70. DOI: 10.1016/j.humpath.2015.10.008. View

Wiegand K, Shah S, Al-Agha O, Zhao Y, Tse K, Zeng T . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532-43. PMC: 2976679. DOI: 10.1056/NEJMoa1008433. View

10.

Guan B, Wang T, Shih I . ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011; 71(21):6718-27. PMC: 3206175. DOI: 10.1158/0008-5472.CAN-11-1562. View

11.

Thorpe L, Yuzugullu H, Zhao J . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2014; 15(1):7-24. PMC: 4384662. DOI: 10.1038/nrc3860. View

12.

Xie C, Fu L, Han Y, Li Q, Wang E . Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma. Tumour Biol. 2014; 35(8):7921-7. DOI: 10.1007/s13277-014-2074-y. View

13.

Wang X, Che K, Shi T, Liu Q, Xu X, Wu H . Loss of ARID1A expression is associated with systemic inflammation markers and has important prognostic significance in gastric cancer. J Cancer Res Clin Oncol. 2022; 148(7):1583-1595. DOI: 10.1007/s00432-022-03971-w. View

14.

Mashtalir N, DAvino A, Michel B, Luo J, Pan J, Otto J . Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes. Cell. 2018; 175(5):1272-1288.e20. PMC: 6791824. DOI: 10.1016/j.cell.2018.09.032. View

15.

Liu N, Rowley B, Bull C, Schneider C, Haegebarth A, Schatz C . BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 2013; 12(11):2319-30. DOI: 10.1158/1535-7163.MCT-12-0993-T. View

16.

Zhou H, Tan S, Li H, Lin X . Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma. Mol Med Rep. 2019; 19(3):2125-2136. PMC: 6390055. DOI: 10.3892/mmr.2019.9886. View

17.

Van Rechem C, Boulay G, Leprince D . HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun. 2009; 385(4):586-90. DOI: 10.1016/j.bbrc.2009.05.115. View

18.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

19.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

20.

Almhanna K, Strosberg J, Malafa M . Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011; 31(12):4387-92. View